Table 1.
Summary of clinical features and outcomes of CALR-mutant ET and MF
| CALR vs JAK2 | CALR vs MPL | CALR vs triple negative | |
|---|---|---|---|
| ET | |||
| Clinical | Younger, male predominance, lower WBC count, lower Hg/Hct, higher platelets | Male predominance, otherwise similar | Male predominance, higher platelets |
| Thrombosis | Decreased risk | Decreased risk | Similar |
| Post-ET MF | Similar to increased | Similar | Similar |
| Overall prognosis | Similar | Similar | Similar |
| PMF | |||
| Clinical | Younger, lower WBC count, higher Hg/Hct, higher platelets | Younger, higher Hg/Hct, higher platelets | Younger, higher Hg/Hct, higher platelets |
| Thrombosis | Similar, possibly decreased risk | Similar | Similar |
| Leukemic transformation | Similar | Similar | Improved |
| Overall prognosis | Improved* | Similar | Improved |
Hct, hematocrit; Hg, hemoglobin; MF, myelofibrosis; WBC, white blood cell.
*
Improved overall survival may be restricted to type 1–like mutations.